Laura E Eldridge, MS CCC-SLP | |
56 East Main Sreet Suite 202, Aron, CT 06001 | |
(860) 965-2103 | |
(860) 217-0742 |
Full Name | Laura E Eldridge |
---|---|
Gender | Female |
Speciality | Speech-language Pathologist |
Location | 56 East Main Sreet Suite 202, Aron, Connecticut |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1598204026 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
235Z00000X | Speech-language Pathologist | 9832 (Massachusetts) | Primary |
Mailing Address | Practice Location Address |
---|---|
Laura E Eldridge, MS CCC-SLP 56 East Main Sreet Suite 202, Aron, CT 06001 Ph: (860) 965-2103 | Laura E Eldridge, MS CCC-SLP 56 East Main Sreet Suite 202, Aron, CT 06001 Ph: (860) 965-2103 |
News Archive
For most American women, their "time of the month" is seen as a hindrance to daily life. In impoverished and developing countries, however, monthly periods are a major cause for concern among women. The lack of affordable, quality sanitary pads results in females missing up to 50 days of school annually - thereby compromising their educational and professional potential.
Using fenofibrate to lower blood fats in people with diabetes reduces the risk of a first diabetes-related amputation by 36 per cent. This is among the conclusions of the FIELD study, reported in an article in this week's diabetes special issue of The Lancet.
A new comprehensive online resource listing national expertise in the design and conduct of clinical trials is launched today. The UKCRC Registered Clinical Trials Units website provides, for the first time, centralised information on Clinical Trials Units (CTUs) in the UK - including the Bristol Randomised Trials Collaboration (BRTC) at the University of Bristol.
The US Food and Drugs Administration (FDA) has approved Byetta (exenatide) injection as add-on treatment for use with insulin glargine, together with exercise and diet for diabetes type 2 patients who are not responding well enough to glargine alone. Byetta's add-on therapy is for those on glargine with metformin and/or a TZD (thiazolidinedione) or without.
› Verified 9 days ago